芒果制药(MGRX)最主要的收入来源是什么？

通过最新财报数据拆解，该公司的收入主要由其核心业务板块与相关服务支持构成。您可以通过页面上的交互式图表直观查看各业务线对总营收的具体贡献比例。

如何直观分析 MGRX 的财务状况与盈利模式？

瓜壳日历通过交互式桑基图(Sankey Diagram)和瀑布图(Waterfall Chart)，将该公司的总营收、销售成本、运营费用以及最终的净利润流程进行了全景可视化，方便投资者一分钟看懂其经营效率与现金流走向。

Income Statement Q1 2026
Item	Category	Value	YoY
Revenues [default label]	revenue	67864	-37.91%
Loss from operations	profit	3.13M	-31.69%
Gross profit	profit	29001	-53.27%
Cost of revenues - related party	cost	30645	36.17%
Cost of revenues	cost	8218	-66.78%
Total operating expenses	cost	3.16M	-31.97%

Balance Sheet Q1 2026
Item	Category	Value
Intangible assets - acquired patents and license, net of amortization	assets	13.94M
Operating lease right-of-use assets	assets	294061
Cash and cash equivalents	assets	174562
Due from related party	assets	20056
Deposits	assets	16957
Property and equipment, net of accumulated depreciation of $3,518 and $3,268	assets	1544
Prepaid expenses	assets	897
Total non-current assets	assets	14.24M
Total current assets	assets	212472
Total assets	assets	14.45M
Non-controlling interest	liabilities	1533
Total stockholders’ equity	liabilities	13.47M
Total liabilities	liabilities	974571
Accumulated deficit	liabilities	44.05M
Accumulated other comprehensive loss	liabilities	3193
Total mangoceuticals, inc. stockholders’ equity	equity	13.48M
Total current liabilities	liabilities	737606
Total long-term liabilities	liabilities	236965
Aggregate	equity	57.53M
Accounts payable and accrued liabilities	liabilities	529800
Other liabilities	liabilities	147451
Operating lease liability, current	liabilities	57058
Payroll tax liabilities	liabilities	3297
Operating lease liability, net of current portion	liabilities	236965
Additional paid in capital	liabilities	57.20M
Stock warrants	liabilities	324288
Common stock (par value $0.0001), 200,000,000 shares authorized, of which 16,967,421 and 15,888,795 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively	liabilities	1698
Preferred stock, value	liabilities	98

Operating Activities – 3M 2026
Item	Value
Options vested for stock-based compensation	1.09M
Issuance of stock and warrants for services or claims	589107
Amortization expense	276815
Increase (decrease) in accounts payable and accrued liabilities	113118
Increase (decrease) in security deposits	16942
Amortization of license agreement	14523
Operating lease right of use asset	13800
Depreciation	250
Increase (decrease) in prepaid expense	120
Increase (decrease) in income taxes payable	-6124
Increase (decrease) in other operating liabilities	-9191
Operating lease right of use liabilities	-13800
Net loss	-3.40M

Cash Balance – 3M 2026
Item	Value
Cash and cash equivalents, beginning of period	1.49M
Cash and cash equivalents, end of period	174562